Investors

Corporate Profile
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
Stock Information
AGLE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.01
Change (%)0.00 (0.00%)
Volume0
Data as of 09/28/16 4:00 p.m. ET
Stock chart for: AGLE.O.  Currently trading at $7.01 with a 52 week high of $12.75 and a 52 week low of $3.89.

Recent NewsMore >>
09/15/16

Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency

– Top-Line Data is Anticipated in the First Half of 2017 – AUSTIN, Texas, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amin

Read More

09/07/16

Aeglea BioTherapeutics Appoints Leading Experts to Inaugural Scientific Advisory Board

AUSTIN, Texas, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today an

Read More

09/01/16

Aeglea BioTherapeutics to Present at the 2016 Wells Fargo Healthcare Conference

AUSTIN, Texas, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today an

Read More

Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.